Autologous stem cell transplant for high‐risk neuroblastoma: Achieving cure with low‐cost adaptations-Reference-Cited by-同舟云学术

Autologous stem cell transplant for high‐risk neuroblastoma: Achieving cure with low‐cost adaptations

Published:2020-03-20 Issue:6 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Jain Richa¹,Hans Rekha²,Totadri Sidharth¹^ORCID,Trehan Amita¹^ORCID,Sharma Ratti Ram²,Menon Prema³,Kapoor Rakesh⁴,Saxena Akshay Kumar⁵,Mittal Bhagwant Rai⁶,Bhatia Prateek¹^ORCID,Kakkar Nandita⁷,Srinivasan Radhika⁸,Rajwanshi Arvind⁸,Varma Neelam⁹,Samujh Ram³,Marwaha Neelam²,Bansal Deepak¹^ORCID

Affiliation:

1. Department of Pediatrics, Pediatric Hematology‐Oncology UnitAdvanced Pediatrics Center Chandigarh India

2. Department of TransfusionPostgraduate Institute of Medical Education and Research Chandigarh India

3. Department of Pediatric SurgeryPostgraduate Institute of Medical Education and Research Chandigarh India

4. Department of RadiotherapyPostgraduate Institute of Medical Education and Research Chandigarh India

5. Departement of RadiodiagnosisPostgraduate Institute of Medical Education and Research Chandigarh India

6. Department of Nuclear MedicinePostgraduate Institute of Medical Education and Research Chandigarh India

7. Department of HistopathologyPostgraduate Institute of Medical Education and Research Chandigarh India

8. Department of CytopathologyPostgraduate Institute of Medical Education and Research Chandigarh India

9. Department of HematologyPostgraduate Institute of Medical Education and Research Chandigarh India

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28273

Reference42 articles.

1. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

2. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study

3. Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

4. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

5. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence Data on Adverse Reactions to Infusion of Thawed Hematopoietic Progenitor Cells: Retrospective Analysis from a Single Center in India;Indian Journal of Medical and Paediatric Oncology;2024-07-22

2. NEUROBLASTOMA CONGÊNITO: DIAGNÓSTICO PRECOCE E REVISÃO DE LITERATURA- UM RELATO DE CASO PROMISSOR;REVISTA FOCO;2024-07-22

3. Perspectives on the Cost and Value of Stem Cell and Emerging Therapies;Comprehensive Hematology and Stem Cell Research;2024

4. Protean Neuroophthalmic Presentations of Common Childhood Malignancies—A Report of Two Cases;Indian Journal of Medical and Paediatric Oncology;2023-05-12

5. Stem cells in degenerative lumbar spine disease: a review and focus on utility in Low- and Middle-Income Countries;Journal of the Pakistan Medical Association;2023-01-25